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1 Research questions 
The EUnetHTA HTA Core Model® for Rapid Relative Effectiveness Assess-
ment of Pharmaceuticals was used for structuring this report [1]. The Model 
organises HTA information according to pre-defined generic research ques-
tions. Based on these generic questions, the following research questions were 
answered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is ofatumumab? 
A0022 Who manufactures ofatumumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ofatumumab received marketing authorisation? 
Health problem and current use 
A0002 What is CLL? 
A0004 What is the natural course of CLL? 
A0006 What are the consequences of CLL for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms of CLL for the patient? 
A0003 What are the known risk factors for CLL? 
A0024 How is CLL currently diagnosed according to published guidelines and in practice? 
A0025 How is CLL currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ofatumumab on mortality? 
D0005 How does ofatumumab affect symptoms and findings (severity, frequency) of CLL? 
D0006 How does ofatumumab affect progression (or recurrence) of CLL? 
D0011 What is the effect of ofatumumab on patients´ body functions? 
D0012 What is the effect of ofatumumab on generic health-related quality of life? 
D0013 What is the effect of ofatumumab on disease-specific quality of life? 
Safety 
C0008 How safe is ofatumumab in relation to the comparator? 
C0002 Are the harms related to dosage or frequency of applying ofatumumab? 
C0005 What are the susceptible patient groups that are more likely to be harmed through  
the use of ofatumumab? 
A0021 What is the reimbursement status of ofatumumab? 
 
 
 
 
EUnetHTA  
HTA Core Model®  
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2 Drug description 
Generic/Brand name/ATC code:  
Ofatumumab/Arzerra®/L01XC10 
B0001: What is ofatumumab? 
Ofatumumab (Arzerra®) is a human monoclonal antibody, which is produced 
in recombinant murine cell lines (NS0) [2]. It binds specifically to CD20 on 
the surfaces of B cells. Thereby, ofatumumab triggers complement-dependent 
cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) 
of CD20 overexpressing B cells. CD20 is a non-glycosylated cell surface phos-
phoprotein that acts as a calcium ion channel. It is only expressed on B cells 
during most stages of B-cell development [3].  
Ofatumumab is available in single-use vials either containing 100 mg/5 mL 
or 1,000 mg/50 mL [4].  
Ofatumumab should be administered as an intravenous infusion. Depend-
ing on the indication, different treatment regimens of ofatumumab are used 
in chronic lymphocytic leukaemia (CLL).  
The recommended dosage for extended treatment in CLL is 300 mg on day 1, 
followed by 1,000 mg on day 8 one week later and subsequently 1,000 mg 7 
weeks later. Thereafter, 1,000 mg every 8 weeks for up to a maximum of two 
years [4].  
 
A0022: Who manufactures ofatumumab? 
Novartis Pharma GmbH 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Ofatumumab maintenance therapy is indicated for the treatment of adult 
patients with relapsed chronic lymphocytic leukaemia (CLL).  
 
 
  
anti-CD20 antibody 
300 mg (D1) 
1,000 mg (D8) 
7 weeks later 1,000 mg 
every 8 weeks 1,000 mg 
indicated as 
maintenance therapy  
of relapsed CLL  
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4 Current regulatory status 
A0020: For which indications has ofatumumab received  
marketing authorisation? 
On 7th November 2008, orphan designation (EU/3/08/581) was granted by the 
European Medicine Agency (EMA) to Glaxo Group Limited, United King-
dom, for ofatumumab for the treatment of CLL. In May 2015, the sponsor-
ship was transferred to Novartis Europharm Limited, United Kingdom [5]. 
Ofatumumab (Arzerra®) was approved by the European Medicines Agency 
(EMA):  
 for the treatment of CLL in patients refractory to fludarabine and 
alemtuzumab (2010). 
 in combination with chlorambucil or bendamustine, indicated for the 
first-line treatment of patients with CLL and for patients who are not 
eligible for fludarabine-based therapy (2014) [2]. 
Ofatumumab (Arzerra®) was approved by the United States Food and Drug 
Administration (FDA): 
 for the treatment of patients with CLL refractory to fludarabine and 
alemtuzumab (2009). 
 in combination with chlorambucil, for the treatment of previously un-
treated patients with chronic lymphocytic leukaemia (CLL) for whom 
fludarabine-based therapy is considered inappropriate (2014). 
 for extended treatment of patients who are in complete or partial re-
sponse after at least two lines of therapy for recurrent or progressive 
CLL (January 2016). 
 
 
 
5 Burden of disease 
A0002: What is CLL? 
A0004: What is the natural course of CLL? 
CLL pertains to the group of indolent B-cell non-Hodgkin lymphomas (NHL). 
It is a disorder of morphologically mature but immunologically less mature 
lymphocytes (white blood cells) and is manifested by advanced accumulation 
of these cells mainly in the blood, bone marrow, and lymphatic tissues [6]. 
In case of CLL lymphocyte counts in the blood are typically greater than or 
equal to 5,000/mm3 with a characteristic immunophenotype (CD5- and CD23-
positive B cells) [7].  
The course of CLL progresses from an indolent lymphocytosis devoid of other 
evident disease to one of generalised lymphatic enlargement with accompa-
nying pancytopenia (reduction of red and white blood cells, as well as plate-
lets). The major cause of death in CLL patients are complications of pancyt-
openia, including haemorrhage and infection [8].  
 
orphan designation  
by the EMA 2008 
 
approved by the EMA 
since 2010 
FDA approval  
since 2009 
FDA approval for 
maintenance treatment 
in CLL since 2016 
indolent B-cell  
non-Hodgkin lymphoma 
CLL progresses from an 
indolent lymphocytosis 
 generalised lymphatic 
enlargement 
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A0006: What are the consequences of CLL for the society? 
A0023: How many people belong to the target population? 
Leukaemia in general affects around 8 in 100,000 of the Austrian population, 
with more than 1,000 people being diagnosed with leukaemia each year. It is 
estimated that 700 people die of the disease per year [9]. CLL is one of the 
most common form of leukaemia in adults in Western countries, accounting 
for approximately 25% to 30% of all leukaemias [10]. The median age of di-
agnosis is at about 70 years, and it occurs more often in males than in females 
(2:1 ratio) [11]. 
 
A0005: What are the symptoms of CLL? 
Discernible signs during physical examination indicating CLL may include 
lymphadenopathy, splenomegaly, hepatomegaly or skin lesions. If symptoms 
occur, they range from painless swelling of lymph nodes to symptoms corre-
sponding to acquired immunodeficiency disorders such as infections or au-
toimmune complications. In the majority of CLL cases any signs or symp-
toms are detectable; only 5–10% of affected patients show the so called „B 
symptoms” [12]: 
 unintentional weight loss ≥ 10% of body weight within the previous 
6 months,  
 fevers of > 38°C for ≥ 2 weeks without evidence of infection, 
 night sweats without evidence of infection, 
 extreme fatigue.  
 
A0003: What are the known risk factors for CLL? 
Risk factors for CLL are a family history of CLL or other lymph-related can-
cers, older age, gender (men are more often affected than women), ethnicity 
(CLL is more common in North America and Europe than in Asia) and cer-
tain chemical exposures (i.e. Agent Orange) [13]. 
 
A0024: How is CLL currently diagnosed according  
to published guidelines and in practice? 
In most instances, CLL is discovered incidentally in the scope of routine blood 
tests, because patients are asymptomatic at the time of diagnosis. The diag-
nosis is established by blood counts, blood smears, and immunophenotyping 
of circulating B-lymphocytes, which identify a clonal B-cell population car-
rying the CD5 antigen as well as B-cell markers [14]. 
There are two existing prognostic staging systems, the Rai and Binet staging 
systems, which are established by physical examination and blood counts. The 
Rai staging system distinguishes three major prognostic groups with distinct 
clinical outcomes [14, 15]:  
 Stage 0: lymphocytosis 
 Stages I to II: lymphadenopathy, organomegaly 
 Stages III to IV: anaemia, thrombocytopenia.  
most common form of 
leukaemia in Western 
countries;  
affects mostly men aged 
about 70 years 
only 5–10% of all  
CLL patients show 
typical symptoms 
risk factors: age, sex, 
ethnicity, family history 
& other cancers 
most patients are 
asymptomatic at 
diagnosis and are 
diagnosed incidentally  
two staging systems  
for CLL: Rai & Binet 
staging systems 
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The Binet staging system is subdivided into three different stages with pa-
tients being classified according to the number of involved sites plus the oc-
currence of anaemia (haemoglobin < 10 g/dL) and/or thrombocytopenia (plate-
lets < 100,000/µL) [15, 16]: 
 Stage A: fewer than three involved lymphoid sites 
 Stage B: three or more involved lymphoid sites 
 Stage C: presence of anaemia and/or thrombocytopenia. 
However, there are patients who are classified as having early-stage disease 
and still show rapid progress in their disease. Therefore, the following addi-
tional prognostic factors have been investigated: presence of certain serum 
markers (thymidine-kinase, beta-2 microglobulin), genetic markers (includ-
ing IGHV mutational status), cytogenetic abnormalities (deletion of 11q, 13q 
and 17p, CD38 expression and ZAP-70 expression) and other genetic lesions 
(including mutations in NOTCH1, SF3B1 and/or BIRK3 genes) [15, 16].  
 
 
 
6 Current treatment 
A0025: How is CLL currently managed according  
to published guidelines and in practice? 
There are several treatment options for CLL dependent on disease stage, pa-
tient’s age and presence of cytogenetic lesions or concomitant disease (Table 
1). Patients diagnosed in an early stage only should be observed [17]. 
Patients with advanced Binet or Rai stages or with active, symptomatic dis-
ease need therapy. The present standard of therapy for physically fit patients 
is chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab. 
Patients in impaired physical conditions should be treated with an anti-CD20 
antibody (obinutuzumab or rituximab or ofatumumab) in combination with 
a milder chemotherapy (chlorambucil) may be applied [14].  
If the disease progresses after a period of six months or after either complete 
or partial remission, it is defined as a relapse [18]. At relapse, the initial treat-
ment may be repeated if the treatment-free interval exceeds two to three years. 
If relapse occurs earlier, the therapy should be adjusted using alternative 
agents like bendamustine (plus rituximab), alemtuzumab, lenalidomide, ofa-
tumumab, ibrutinib or idelalisib. Patients with a del(17p) or TP53 mutation 
may be treated with ibrutinib or a combination of idelalisib and rituximab. 
Allogeneic stem cell transplantation (SCT) can be considered in relapsing 
patients with TP53 mutations or del(17p) or patients that are refractory (no 
response to therapy) to repeated chemo- or immunotherapies [14]. 
 
 
  
additional  
prognostic factors 
treatment options 
depending on stage, 
age, cytogenetic lesions 
& other diseases 
treatment options  
for relapsed CLL 
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Table 1: Treatment algorithm for CLL patients in first- and second-line indications [14] 
CLL 1st line treatment 
Stage Fitness 
Del(17p) 
p35mut Therapy 
Binet A–B,  
Rai 0-II, inactive 
Irrelevant Irrelevant None 
Active disease or 
Binet C or Rai  
III–IV 
Go go1 No Fludarabine + cyclophosphamide + rituximab (FCR) 
(bendamustine + rituximab above 65 years?) 
Yes Ibrutinib, idelalisib + rituximab (Allogeneic SCT) 
Slow go2 No Chlorambucil + obinutuzumab or + rituximab or + ofatumumab 
Yes Ibrutinib, alemtuzumab, HD of rituximab or ofatumumab 
CLL 2nd line treatment 
Response to 
1st line therapy Fitness Therapy 
  Standard Alternatives (trials) 
Refractory or 
progression 
within 2 years 
Go go1 Ibrutinib, A-Dex, 
fludarabine + 
alemtuzumab, FCR 
 allogeneic SCT (?) 
Lenalidomide, bendamustine + rituximab,  
(other kinase inhibitors, ABT-199) 
Slow go2 Change therapy  
(include in trial) 
Ibrutinib, idelalisib + rituximab, alemtuzumab for del(17p), 
ABT-199, FCR-lite, bendamustine + rituximab, lenalidomide, 
ofatumumab, HD of rituximab 
Progression  
after 2 years  
All Repeat 
 1st-line therapy 
 
Abbreviations: C = cyclophosphamide, CLL = chronic lymphocytic leukaemia, DEX = dexamethasone, F = fludarabine,  
HD = high dose, R = rituximab, SCT = stem cell transplantation  
 
 
 
7 Evidence 
A literature search was conducted on 29 January 2016 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were „Ofatumumab”, „Arzerra”, „HuMax-CD20”, „chronic lym-
phocytic leukaemia”, „CLL”, „relapsed” and „maintenance”. Overall, 180 ref-
erences were identified through systematic literature search. Also, the man-
ufacturer was contacted and submitted one article and further information, 
which had already been identified through the literature search. Eligible for 
inclusion were phase III trials (full text, abstracts) and phase II studies pub-
lished as full text, but also other study designs like results from compassion-
ate-use programmes or meta-analyses. After applying these inclusion crite-
ria, one phase III trial and no phase II trial were included in this report. Ad-
ditionally, 26 references were identified through hand search. 
                                                             
1 Go go = good physical condition of patients, defined by a normal creatinine clear-
ance and a low score at the “cumulative illness rating scale” (CIRS) 
2 Slow go = impaired physical condition of patients 
systematic search in 
5 databases: 180 hits 
 
included: 1 phase III trial 
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7.1 Clinical efficacy and safety – phase III studies 
PROLONG [19] is an open-label, multicentre, randomised phase III study 
comparing ofatumumab maintenance treatment to observation of patients in 
remission after reinduction treatment for relapsed chronic lymphocytic leu-
kaemia. Reported are the results of a prespecified interim analysis, where 
two thirds of the planned study events (disease progression or death) had oc-
curred.  
A total of 474 patients were randomly assigned in a 1:1 ratio to receive either 
ofatumumab at a dose of 300 mg followed by 1,000 mg 1 week later and every 
8 weeks for up to 2 years or to undergo observation. The randomisation was 
stratified, in a block size of four, due to clinical response at entry (complete 
remission or partial remission), number of previous induction treatments (two 
or three) and type of latest prior treatment (chemoimmunotherapy, alkylat-
ing monotherapy only or other treatment).  
The median duration of follow-up at the time of data cut-off (June 2014) was 
19.1 months, ranging from 10.3 to 28.8. From 238 patients of the ofatumumab 
group, 59 (25%) had received all 13 cycles of ofatumumab were as 205 (86%) 
patients had received all assigned treatment doses. 78 events were recorded 
in the ofatumumab group (74 progression and four deaths), while 120 events 
were recorded in the observation group (116 progressions and four deaths). 
Enrolled patients were at least 18 years or older (ranging from 33 to 87 years) 
with a diagnosis of CLL in complete or partial remission after second- or 
third-line therapy on the basis of the International Workshop on Chronic 
Lymphocytic Leukaemia’s (IWCLL) updated National Cancer Institute-spon-
sored working group (NCI-WG) criteria and a WHO performance status be-
tween 0 and 2. Detailed patient characteristics including inclusion and ex-
clusion criteria can be found in Table 4. 
The primary outcome of PROLONG was investigator-assessed progression-
free survival (PFS); secondary outcomes were overall survival (OS), time to 
next treatment (TTNT), progression-free survival after next-line therapy, safe-
ty outcomes including adverse events (measured using the National Cancer 
Institute’s (NCI) common terminology criteria for adverse events, version 4.0). 
β-2 microglobulin (β2M), serum immunoglobulin concentrations and IGHV 
mutation status were measured by standard techniques within 14 days be-
fore treatment started. Quality-of-life (QoL) was assessed via EORTC core 
and quality-of-life questionnaires: QLQ-C30 and QLQ-CLL16.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect  
of ofatumumab on mortality? 
Compared with the observation group the hazard ratio (HR) of death was 
0.85 (95% CI 0.52–1.37, p = 0.4877 by a log-rank test) in the ofatumumab 
group with no evidence for a difference between the two groups. Median OS 
data for the two groups were not available, neither in the results of the inter-
im analyses nor in the supplementary appendix to the study. 
 
PROLONG:  
a randomised phase III 
study in 474 patients  
comparison of 
ofatumumab vs. 
observation  
median follow-up  
duration at the time  
of data cut-off  
 19.1 months 
patients aged ≥ 18 years, 
second or third 
complete or partial 
remission,  
WHO: 0–2 
primary outcome:  
PFS 
no evidence for  
a difference in OS 
between the two groups 
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D0006: How does ofatumumab affect progression (or recurrence) of CLL? 
The primary endpoint, by physical examination investigator-assessed PFS, 
was significantly improved (p < 0.0001) in the ofatumumab group compared 
to the observation group. The median investigator-assessed PFS by physical 
examination (palpatory measurement of lymph nodes and organs) was 29.4 
months (95% CI 26.2–34.2) in the ofatumumab group and 15.2 months (95% 
CI 11.8–18.8) in the observation group. The HR for disease progression for 
ofatumumab compared to observation was 0.50 (95% CI 0.38–0.66). Overall 
PFS results were consistent across all subgroups irrelevant of baseline char-
acteristics (age, sex, remission status at study start, previous treatments, base-
line minimal residual disease, cytogenetic abnormalities, beta-2M concentra-
tion or mutational status).  
Similar estimates of median PFS (30.4 months (95% CI 25.3–35.6) in the 
ofatumumab group vs. 14.8 months (95% CI 11.3–21.2) in the observation 
group; HR 0.55 (95% CI 0∙42–0.72); p < 0.0001) had been found by an inde-
pendent review committee (Parexel International, Waltham, MA, USA).  
In both groups, slightly shorter PFS could be observed in the investigator-
assessed PFS by computer tomography (CT) scan compared to assessment by 
physical examination. Median PFS was 23.7 months (95% CI 22.8–28.9) in 
the ofatumumab group and 13.5 months (95% CI 11.4–21.2) in the observa-
tion group. The HR for disease progression for ofatumumab compared to ob-
servation was 0.66 (95% CI 0.50–0.87; p = 0.002). 
 
D0005: How does ofatumumab affect symptoms and findings  
(severity, frequency) of CLL? 
There were no response rate data available. 
 
D0011: What is the effect of ofatumumab on patients’ body functions? 
No evidence was found to answer this research question.  
 
D0012: What is the effect of ofatumumab on generic  
health-related quality of life? 
D0013: What is the effect of ofatumumab on disease-specific quality of life? 
Between the two groups no clinically relevant differences regarding health-
related quality of life (HRQoL) could be found at any time point during 
treatment. Using the EORTC QLQ-C30 (global health status domain), a 
mean reduction of 0.2 points (standard deviation (SD) 38.5) in the ofatum-
umab group and a mean reduction of 1.9 points (SD 38.5) in the observation 
group were detected. Concerning the B-symptoms index, a repeated measures 
analysis of all time points demonstrated that patients in the ofatumumab 
group had no change in symptoms from baseline to the end of 2 years of 
treatment (mean points change 0.01 (SD 27.7), whilst patients in the obser-
vation group reported a worsening of symptoms (mean points change 2.8 
(SD 26.2); p = 0.002). In the QLQ-CLL16 questionnaire patients were asked 
about worry for future health. Concerning this question, patients who had 
been treated with ofatumumab were less worried than patients in the obser-
vation group (four points difference, p = 0.06); being in an open-label study 
the patients were not blinded to their treatments. 
significantly improved 
PFS in the ofatumumab 
group across all 
subgroups 
PFS results by an 
independent review 
committee 
investigator assessed 
PFS by CT scan 
no clinically relevant 
difference in HRQoL 
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Table 2: Efficacy results of the PROLONG trial 
Descriptive 
statistics and 
estimate 
variability 
Treatment group Ofatumumab Observation 
Number of subjects 238 236 
PFS3 median (95% CI), months 29.4 (26.2–34.2) 15.2 (11.8–18.8) 
PFS – IRC4 median (95% CI), months 30.4 (25.3–35.6) 14.8 (11.3–21.2) 
PFS – CTS5 median (95% CI), months 23.7 (22.8–28.9) 13.5 (11.4–21.2) 
TTNT median (95% CI), months 38.0 (28.3–NR) 31.1 (21.6–NR) 
Effect estimate 
per comparison 
Comparison group Ofatumumab vs. Observation 
PFS3 HR 0.50 
95% CI 0.38–0.66 
Log-rank test p value < 0.0001 
OS HR 0.85 
95% CI 0.52–1.37 
Log-rank test p value 0.4877 
TTNT HR 0.66 
95% CI 0.47–0.92 
Log-rank test p value 0.011 
PFS after next treatment HR 1.00 
95% CI 0.48–2.07 
Log-rank test p value 0.9977 
Abbreviations: CI = confidence interval, HR = hazard ratio, NR = not reached, OS = overall survival,  
PFS = progression-free survival, TTNT = time to next treatment 
 
7.1.2 Safety 
C0008: How safe is ofatumumab in relation to the comparator(s)? 
The ofatumumab group showed a higher total number of adverse events (AEs) 
as well as a higher number of grade 3 or higher adverse events than the ob-
servation group. The most frequent grade ≥ 3 AEs (up to 60 days after the 
last treatment) were neutropenia and infections. In post-hoc analyses the ofa-
tumumab group showed an increased incidence of grade 3 or higher neutro-
penia compared to the observation group (p = 0.0001). Prolonged and severe 
neutropenia6 occurred more frequently in the ofatumumab group than the 
observation group (5%, n = 13/237 vs. 2%, n = 5/237). Additionally, the inci-
dence of grade 3 or higher infections increased and was more prevalent in the 
ofatumumab group (31 (13%) of 237 patients) than in the observation group 
(20 (8%) of 237 patients) (p = 0.11). 42 patients (18%) of the ofatumumab 
group needed growth factor support (G-CSF) compared to 17 patients (7%) 
of the observation group.  
                                                             
3 Investigator-assessed PFS by physical examination  
4 PFS – IRC = assessed by an independent review committee 
5 PFS – CTS = investigator-assessed PFS by CT scans  
6 Prolonged and severe neutropenia = grade 3 or 4 neutropenia experienced during 
the treatment phase and not resolving within 42 days of the last dose 
more grade ≥ 3 AEs in 
the ofatumumab group  
 
 
higher incidence of 
grade ≥ 3 neutropenia  
& infection in the 
ofatumumab arm 
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At study entry, serum immunoglobulin concentrations were lower than nor-
mal in both study groups. The ofatumumab group showed no change in these 
concentrations during treatment, however, serum concentrations of Immuno-
globulin M (IgM) increased during follow-up. 3 months after the end of ofa-
tumumab treatment peripheral blood B cells began to recover; however, they 
had not yet reached normal levels at the end of follow-up.  
In 8% of patients in the ofatumumab group and in 1% of patients in the ob-
servation group, AEs led to permanent discontinuation of treatment. Between 
the first dose and 60 days afterwards, two patients in the ofatumumab and 
five patients in the observation group died because of AEs. A total of 66/474 
(14%) patients died, 31 of these deaths were due to progressive disease. None 
of these deaths could be ascribed to the study drug. No Richter transforma-
tion7 could be detected in the ofatumumab group compared to two in the 
observation group. 
Infusion-related reactions were rarely detected, 36 patients in the ofatumumab 
arm showed grade 1 or 2 reactions, whereas grade 3 reactions were reported 
in three patients treated with ofatumumab, and there were no reports of in-
fusion related reactions in the observation group. No grade 4 or 5 infusion-
related reactions were reported. All treatment-related AEs can be found in 
Table 3. 
 
C0002: Are the harms related to dosage or frequency  
of applying ofatumumab? 
No evidence was found to answer this research question.  
 
C0005: What are the susceptible patient groups  
that are more likely to be harmed through the use of ofatumumab?  
Anti-CD20 monoclonal antibodies carry a risk of hepatitis B reactivation 
among patients positive for HBsAg or anti-HBc. Prior to treatment all pa-
tients should be screened for hepatitis B. Patients with verification of prior 
hepatitis B infection should be monitored for clinical and laboratory signs of 
reactivation during therapy and after completion of therapy. Immunothera-
py should be discontinued in patients with reactivated hepatitis [19]. 
  
                                                             
7 Richter transformation = transformation of CLL to a highly aggressive non-Hodgkin 
lymphoma  
peripheral blood B cells 
started to recover  
after ofatumumab 
maintenance treatment 
a total of 66 patients 
died; no deaths were 
attributed to the  
study drug 
36 patients of the 
ofatumumab arm 
showed grade 1/2 
infusion-related 
reactions 
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Table 3: Treatment-related adverse events reported by investigator8  
Adverse Event  
(according to CTCAE version 4.0) 
Ofatumumab  
(n = 237) 
Observation  
(n = 237) 
Any grade 5, n (%) 1 (< 1) 6 (< 4) 
 Grade ½ 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Grade ½ 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Neutropenia  10 (4) 33 (14) 23 (10) 4 (2) 13 (5) 10 (4) 
Cough  48 (20) 2 (1) 0 22 (9) 0 (0) 0 
Upper respiratory tract infection  42 (18) 3 (1) 0 22 (9) 1 (<1) 0 
Pyrexia  33 (14) 4 (2) 0 22 (9) 2 (1) 0 
Pneumonia  9 (4) 11 (5) 5 (2) 5 (2) 9 (4) 1 (< 1) 
Fatigue  27 (11) 0 (0) 0 16 (7) 0 0 
Diarrhoea  32 (14) 1 (<1) 0 9 (4) 0 0 
Infusion-related reaction9 36 (15) 3 (1) 0 0 0 0 
Bronchitis  19 (8) 2 (1) 0 15 (6) (< 1) 0 
Thrombocytopenia  15 (6) 2 (1) 2 (1) 7 (3) 5 (2) 5 (2) 
Rash  22 (9) 1 (< 1) 0 10 (4) 0 0 
Sinusitis  17 (7) 2 (1) 0 11 (5) 0 0 
Arthralgia  16 (7) 1 (< 1) 0 11 (5) 1 (< 1) 0 
Pruritus  20 (8) 1 (< 1) 0 7 (3) 0 0 
Respiratory tract infection  11 (5) 1 (< 1) 0 13 (5) 0 1 (< 1) 
Headache  20 (8) 1 (< 1) 0 5 (2) 0 (0) 0 
Herpes zoster  10 (4) 3 (1) 0 7 (3) 1 (< 1) 0 
Back pain  11 (5) 1 (< 1) 0 8 (3) 0 (0) 0 
Urinary tract infection  8 (3) 1 (< 1) 0 7 (3) 1 (< 1) 1 (< 1) 
Insomnia  12 (5) 1 (< 1) 0 5 (2) 0 0 
Dyspnoea  9 (4) 1 (< 1) 0 5 (2) 0 0 
Asthenia  6 (3) 1 (< 1) 0 9 (4) 0 0 
Hypertension  7 (3) 3 (1) 0 5 (2) 0 0 
Febrile neutropenia  2 (1) 5 (2) 3 (1) 0 3 (1) 1 (< 1) 
Hypogammaglobulinaemia  9 (4) 2 (1) 0 0 2 (1) 0 
ALT increased  7 (3) 1 (< 1) 0 2 (1) 0 0 
Decreased appetite  7 (3) 1 (< 1) 0 1 (< 1) 0 0 
Weight decreased 2 (1) 1 (< 1) 0 5 (2) 0 0 
Abbreviations: ALT = alanine aminotransferase, CTCAE = Common Terminology Criteria for Adverse Events 
 
 
7.2 Clinical effectiveness and safety – further studies 
No further study results on ofatumumab from phase II/III trials in the re-
viewed indication (ofatumumab maintenance treatment with relapsed chronic 
lymphocytic leukaemia) are available yet.  
                                                             
8 occurring in at least 2% of patients, any grade 
9 Infusion-related reactions = events occurring during infusion or within 24 hours 
after completion of infusion, includes chills, dyspnoea, flushing, hypotension, nau-
sea, pain, pruritus, pyrexia, rash, and urticaria 
no further studies  
in reviewed indication 
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8 Estimated costs 
A0021: What is the reimbursement status of ofatumumab? 
In Austria, ofatumumab (Arzerra®) is available in vials of 5 mL (100 mg) in 
a package with 3 vials at € 673.80 and vials of 50 mL (1,000 mg) at € 2,172.05 
[20]. 
In patients with relapsed CLL in remission after re-induction treatment, the 
recommended and FDA approved dosage for maintenance treatment is a dose 
of 300 mg on day 1 followed by 1,000 mg one week later (day 8) and every 8 
weeks for up to a maximum of two years [4, 21]. According to this treatment 
regimen, costs for the first cycle (day 1: 3 x 100 mg vials, day 8: 1 x 1,000 mg 
vial) of ofatumumab are € 2,845.85; for additional 23 months of ofatumumab 
maintenance treatment, costs of € 24,978.58 would incur. A treatment of two 
years with ofatumumab including cycle 1 and 8-week intervals would cost 
€ 27,824.43. 
Additional costs would incur due to premedication (acetaminophen, 1,000 mg, 
oral, antihistamine – diphenhydramine, 50 mg, intravenous or oral, and a 
glucocorticoid – prednisolone, 50 mg, intravenous) prior to each infusion of 
ofatumumab [21]. 
 
 
 
9 Ongoing research 
In February 2016, a search in databases www.clinicaltrials.gov   
and www.clinicaltrialsregister.eu was conducted; one ongoing phase III trial 
investigating ofatumumab in patients with relapsed CLL could be identified 
and two which use ofatumumab as a control:  
 NCT00824265: An open-label, randomised trial evaluating the safety 
and efficacy of ofatumumab added to fludarabine-cyclophosphamide 
in patients with relapsed CLL. The estimated study completion date 
is October 2017. 
 NCT01578707: A randomised, multicentre, open-label, phase III study 
of the bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) 
versus ofatumumab in patients with relapsed or refractory CLL/small 
lymphocytic lymphoma (SLL). The estimated study completion date 
is December 2017. 
 NCT02004522: A phase III study of duvelisib versus ofatumumab in 
patients with relapsed or refractory CLL/SLL (DUO). The estimated 
study completion date is June 2021. 
Several phase I and phase II studies are currently conducted (NCT01465334, 
NCT01532700, NCT01809847, NCT01497496, and NCT01294579). 
 
 
 
300 mg: € 673.80 
1,000 mg: € 2,172.05 
2 years’ treatment:  
€ 27,824.43 
1 ongoing phase III study 
in patients with  
relapsed CLL 
ofatumumab  
is investigated in  
various studies 
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10 Discussion 
Ofatumumab (Arzerra®) was approved by the FDA (based on the PROLONG 
trial) in January 2016 for extended treatment of patients who are in complete 
or partial response after at least two lines of therapy for recurrent or progres-
sive CLL [4]; the EMA has not granted marketing authorisation for this in-
dication yet. 
The FDA approval was based on the results of the PROLONG [21] trial, a 
randomised, open-label phase III study. 474 previously treated patients were 
randomised to either observation or ofatumumab intravenously. Results 
showed a significant increase in PFS (investigator-assessed PFS by physical 
examination) in patients who received ofatumumab; patients receiving ofa-
tumumab gained 14.2 months in median compared to the observation arm. 
Median TTNT was also improved among patients who received ofatumumab: 
it was 38.0 months in the ofatumumab group compared to 31.1 months in 
the observation group. Nevertheless, no statistically significant difference be-
tween the two study arms could be detected in OS (HR 0.85, p = 0.4877). 
However, it must be noted that efficacy and toxicity results of the PROLONG 
trial are based on a prespecified interim analysis. It provides results on two 
thirds of the planned study events after 66 patients died (14%) and disease 
progression could be observed in 190 patients. In this respect, a complete da-
ta set will be of interest to see whether the difference in PFS will increase 
further or decreases between the treatment groups.  
QoL results showed no difference between the two treatment groups at any 
time point. But as the provided results are interim analyses, the full dataset 
will be necessary to definitively exclude negative effects on QoL.  
Although overall PFS outcomes were consistent across all subgroups irrele-
vant of baseline characteristics, the results of the cytogenetic subgroups (high-
risk patients: del(17p) and del(11q)) and of the patients who showed a com-
plete response at study entrance should be interpreted with caution due to 
the low number of investigated patients. To identify any advantages or dis-
advantages, these subgroups should be examined further. 
The total rates of treatment-related AEs and those with grades 3–5 were more 
frequent in patients of the ofatumumab group compared to patients in the 
observation group. The most common grade ≥ 3 AEs were neutropenia and 
infections. Post-hoc analysis showed an increase in frequency of grade ≥3 
neutropenia as well as a higher frequency of prolonged and severe neutro-
penia in the ofatumumab arm. Furthermore, the percentage of discontinua-
tion (8%) in the ofatumumab group and the fact that only 25% of patients 
received all 13 cycles of ofatumumab should be taken into consideration. 
Therefore, the long-term side effect profile of ofatumumab will have to be 
analysed further since side effects can compromise QoL in the long term if 
ofatumumab is continuously used. 
It should be noted that the primary outcome of the study (PFS) is a surro-
gate parameter for OS. However, in contrast to the PFS outcomes, OS results 
showed no significant difference between the two study arms. This could be 
due to the fact that unlike with OS, in which the date of death is precise, the 
date of progression is subject to measurement error and other kinds of bias 
(i.e. attrition bias) [22]. Another possible explanation, which has not been 
indication approved  
by the FDA, but not by 
the EMA 
PROLONG: 
improvement in PFS  
& TTNT, but not in OS, 
in patients receiving 
ofatumumab 
efficacy & safety results 
are based on interim 
analysis 
efficacy in subgroups 
total rates & grades  
≥ 3 treatment-related 
AEs are more frequent 
in the ofatumumab arm 
significant PFS results, 
without a survival 
impact 
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properly investigated yet, could be that following initial delay of progression 
the agent caused evolutionary changes in tumours, resulting in the emergence 
of a more aggressive phenotype after treatment [23-25].  
Furthermore, an extended follow-up should be considered to investigate wheth-
er this could be a reason why ofatumumab maintenance treatment has no 
impact on OS. 
Additionally, if the primary outcome of a study is PFS, patients and investi-
gators should preferably be blinded to avoid assessment bias. Since this was 
not the case in PROLONG, there is an increased risk of assessment bias in 
this study [26].  
In the PROLONG trial [21], PFS was censored at the time of last follow-up 
for patients who neither had disease progression nor died. Furthermore, PFS 
was also censored for patients who received new anticancer treatment before 
disease progression and for patients who missed two or more visits. As cen-
soring is incrementally recognised as a potential risk of bias, affecting esti-
mates of PFS in randomised trials, the number of censored patients at each 
time interval should be reported for a better understanding of its possible ef-
fects [27]. 
Two other phase III trials of anti-CD20 antibody maintenance treatment in 
CLL were reported [28, 29]. Both compared rituximab maintenance treat-
ment to observation; both showed an improvement in PFS, with high-risk 
patients (del(11q) and del(17p)) in one study also exhibiting an improvement 
in OS. Thus, it would be interesting to directly compare ofatumumab with 
rituximab to determine from which drug patients benefit the most. Another 
consideration might be the addition of chlorambucil or other agents to anti-
CD20 monoclonal antibodies for treatment of young or middle-aged patients, 
as this is assumed to result in higher response rates [19]. 
Besides the potential for improved clinical outcomes, the rationale for com-
bination therapies is to avoid the development of resistance. This mechanism 
has not been well documented yet. A study from Baig et al. [30] showed that 
the optimal efficacy of CD20-targeted therapy for CLL requires the deter-
mination of a dose size and frequency that optimises the killing of CLL cells, 
without exceeding the capacity of the cytotoxic mechanisms and thereby re-
ducing the loss of CD20 expression in the surviving CLL cells. Therefore, 
long-term data would be necessary to exclude the risk of developing a re-
sistance with the currently used dosage of ofatumumab.  
Another concern to be addressed are the costs for ofatumumab treatment. 
Compared to the standard of care, i.e. observation until disease progression, 
costs are much higher (2 years of treatment: € 27,824.43) for ofatumumab 
maintenance treatment. It will also be of interest to compare costs associated 
with various therapeutic strategies as well as with new agents. Depending on 
the treatment duration and the costs associated with the required premedi-
cation, the costs for ofatumumab may be considerably higher.  
Although the costs are high for ofatumumab compared to observation treat-
ment, the significant improvement of PFS due to ofatumumab maintenance 
treatment should not be neglected. However, the lack of a prolonged gain in 
OS in addition to the increased rate of AEs highlight the requirement of long-
term data on efficacy and safety as well as on the potential risk of developing 
resistance needs to be stressed. Furthermore, differences in clinical benefit 
for specific cytogenetic subgroups, especially del(17p) and del(11q), should 
be further examined. 
open-label study design 
led to a higher risk of 
assessment bias 
effects of censoring  
on PFS results 
two other phase III trials 
investigating anti-CD20 
antibody maintenance 
treatment 
prevention of  
resistance 
higher costs than 
standard of care 
significant improvement 
of PFS but no benefit  
in OS, and higher rates 
of AEs  
 
long-term data required 
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12 Appendix 
Table 4: Characteristics of the PROLONG trial 
Title: Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG):  
an open-label, multicentre, randomised phase III study [21, 31] 
Study identifier NCT01039376, EudraCT number 2009-012518-39, PROLONG 
Design Phase III, randomised, international, multicentre, open-label trial,  
cross-over was not allowed as well as dose reductions 
Duration Enrolment: 2010-05-6 to 2014-06-19 
Median follow-up (at the time of data cut-off):  
19.1 months (IQR 10.3 to 28.8) 
Cut-off date for analyses: 2014-06-16  
(prespecified interim analysis) 
Hypothesis Superiority 
This study was designed and powered to detect differences in PFS between the two 
investigated groups. The planned sample size of the study was 478 patients to detect at least 
a 40% improvement in PFS (HR 0.71), with 80% power and a two-sided α error of 0.05.  
Funding  Novartis Pharma GmbH 
Treatments groups Intervention (n = 238) Ofatumumab administered intravenously at a dose of 
300 mg at Day, 1,000 mg on Day 8 and every 8 weeks 
for up to a maximum of two years 
Control (n = 236) observation 
Endpoints and 
definitions 
Progression-free survival 
(primary outcome) 
PFS Time from randomisation to the earliest date of 
disease progression or death due to any cause 
Overall survival OS Time from randomisation until date of death due to 
any cause 
Time to next treatment TTNT Time from end of primary treatment to institution  
of next therapy [32] 
Progression-free survival 
after next-line therapy 
PFS after 
next-line 
therapy 
Time from randomisation until progression or  
death after next-line therapy 
Database lock NR 
Results and Analysis  
Analysis description Primary Analysis 
All efficacy analyses were done in the intention-to-treat population. Safety analyses included 
all patients who were randomly assigned to treatment, grouped based on the actual treatment 
received (per protocol). Log-rank tests (adjusted for the stratification factors) were used to 
analyse PFS, OS, TTNT and PFS after next-line therapy. All p values are two-sided. Kaplan-Meier 
curves were generated to graphically show the differences between the survival distributions 
of the treatment groups.  
Analysis population  Inclusion  Age ≥ 18 years 
 Diagnosis of CLL in second or third complete or partial remission  
(based on IWCLL updated NCI-WG criteria)  
 WHO performance status of 0–2  
 response assessment within the previous 3 months 
Exclusion  have refractory disease 
 autoimmune haemolytic anaemia requiring treatment 
 chronic or active infection requiring treatment 
 previously received maintenance treatment or autologous or allogeneic 
stem-cell transplant 
 neutrophil count less than 1.0 × 10⁹ cells per L 
 platelet count less than 50 × 10⁹ platelets per L 
 creatinine more than 1.5 times the upper limit of normal (ULN) 
 total bilirubin, alanine aminotransferase, and aspartate aminotransferase 
more than 2.5 times the ULN 
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Title: Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG):  
an open-label, multicentre, randomised phase III study [21, 31] 
Study identifier NCT01039376, EudraCT number 2009-012518-39, PROLONG 
Analysis population  
(continuation) 
Characteristics Intervention Control 
 Median age10 (range), years 64.0 (33–86) 65.0 (39–87) 
Gender: n (%) ♂: 161 (68) 
♀: 77 (32) 
♂: 159 (67) 
♀: 77 (33) 
Median time since diagnosis (range), years  6.0 (1-22) 5.0 (1-22) 
Response to last CLL treatment, n (%): 
CR 
PR 
Missing 
 
45 (19) 
193 (81) 
0 (0) 
 
46 (19) 
189 (80) 
1 (<1) 
Baseline minimal residual disease, n (%): 
Negative 
Positive 
Missing 
 
31 (13) 
137 (58) 
70 (29) 
 
41 (17) 
107 (45) 
88 (37) 
Number of previous treatments, n (%): 
2 
3 
Other 
 
168 (71) 
66 (28) 
4 (2) 
 
166 (70) 
62 (26) 
8 (3) 
Type of last previous treatment, n (%): 
Chemoimmunotherapy 
BR 
FCR 
FR 
Other 
RCVP 
Alkylating monotherapy 
Other 
 
191 (80) 
46 (24) 
100 (52) 
4 (2) 
28(15) 
13 (7) 
14 (6) 
33 (14) 
 
189 (80) 
47 (25) 
103 (54) 
5 (3) 
23 (12) 
11 (6) 
9 (4) 
38 (16) 
Baseline cytogenetics11, n (%): 
Deletion 11q 
Deletion 17p 
Deletion 6q or 12q trisomy or deletion 13q 
No aberration 
Missing 
 
15 (6) 
7 (3) 
44 (18) 
150 (63) 
22 (9) 
 
12 (5) 
4 (2) 
16 (7) 
171 (72) 
33 (14) 
IgHV mutational status, n (%): 
Mutated  
Not mutated  
Not available or missing 
 
47 (20) 
129 (54) 
62 (26) 
 
66 (28) 
108 (46) 
62 (26) 
Abbreviations: CLL = chronic lymphocytic leukaemia, BR = bendamustine plus rituximab, FCR = fludarabine,  
cyclophosphamide, plus rituximab, FR = fludarabine plus rituximab, OS = overall survival, PFS = progression-free survival, 
RCVP = rituximab, cyclophosphamide, vincristine, and prednisolone, IgHV = immunoglobulin heavy chain variable region genes, 
TTNT = time to next treatment. 
 
 
                                                             
10 Age was calculated from birth date to screening date in years 
11 12% cut-off (i.e., at least 12% of chromosome interphases should have the specific chromosomal abnormality for 
the patient to be scored as having deletion 11q, deletion 17p, etc.) 
